Introduction {#Sec1}
============

Antiplatelet therapy is very important following percutaneous coronary intervention (PCI) to reduce the risk of post-interventional complications. However, bleeding risk might be a limiting factor of these blood thinners \[[@CR1]\]. New generation P2Y~12~ inhibitors (ticagrelor and prasugrel) might soon replace clopidogrel for the post-interventional treatment of patients with acute coronary syndrome (ACS) \[[@CR2]\]. This was indicated in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38) and the PLATelet inhibition and patient Outcomes (PLATO) trials \[[@CR3], [@CR4]\].

The newer antiplatelet agents ticagrelor and prasugrel have faster and stronger platelet inhibition in comparison to the commonly used clopidogrel \[[@CR5]\] following coronary angioplasty and hence the European guidelines now recommend both antiplatelet drugs as first-line choice for the post-interventional treatment of patients with ACS \[[@CR6]\].

Recently, a few meta-analyses based on the general population comparing the efficacy and safety of ticagrelor versus prasugrel were published. However, controversial issues were observed. For example, a head-to-head comparison by Bundhun et al. showed comparable outcomes between ticagrelor and prasugrel for the treatment of patients with ACS \[[@CR7]\]. Bleeding events were also similarly observed. Nevertheless, another head-to-head comparison by Sakurai et al. showed prasugrel to be associated with lower risk of bleeding events in comparison to ticagrelor \[[@CR8]\].

Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombosis due to platelet dysfunctions \[[@CR9]\]. Clopidogrel hyporesponsiveness was also observed in this subgroup of patients following PCI \[[@CR10]\]. However, those newer potent antiplatelet agents were not systematically compared in a subgroup of patients with T2DM.

In this analysis, we aimed to systematically compare the post-interventional clinical outcomes and bleeding events observed with ticagrelor versus prasugrel in patients with T2DM.

Methods {#Sec2}
=======

Search Strategies (Data Sources, Search Terms, Inclusion and Exclusion Criteria) {#Sec3}
--------------------------------------------------------------------------------

The database of EMBASE ([www.sciencedirect.com](http://www.sciencedirect.com)), MEDLINE including its subset PubMed, the Cochrane Central Register of Controlled Trials, and [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) were carefully searched for publications comparing the post-coronary interventional outcomes following ticagrelor versus prasugrel use in patients with T2DM. Articles which were published in English were considered relevant to this analysis.

"Ticagrelor, prasugrel and percutaneous coronary intervention", "ticagrelor, prasugrel, percutaneous coronary intervention and diabetes mellitus", "ticagrelor, prasugrel, diabetes mellitus", "ticagrelor, prasugrel, coronary artery diseases", "prasugrel, ticagrelor, acute coronary syndrome", "ticagrelor, prasugrel, coronary angioplasty", "prasugrel, ticagrelor, myocardial infarction" were the search terms which were used.

The inclusion criteria were:Randomized or non-randomized trials comparing the post-interventional clinical outcomes and bleeding events in T2DM patients following treatment with ticagrelor versus prasugrelStudies which involved data that could be used to carry out this analysis

The exclusion criteria were:Meta-analyses, literature reviews, and letters to editorsStudies which did not report the corresponding endpointsStudies only reporting platelet aggregation without considering the post-interventional endpoints or bleeding eventsStudies that included data which could not be used in the analysisDuplicated studies

Types of Participants and Outcomes Reported {#Sec4}
-------------------------------------------

All the participants were T2DM patients with coronary artery disease of different degree (ST and non-ST segment elevated myocardial infarction, ACS) who recently underwent PCI and who were treated with either ticagrelor or prasugrel.

The outcomes reported in each study and the corresponding follow-up time periods are listed in Table [1](#Tab1){ref-type="table"}.Table 1Types of participants, outcomes reported, and follow-up time periodsStudiesTypes of PCI participantsOutcomes reportedFollow-up time periodAlexopoulos 2012 \[[@CR15]\]T2DM patients with STEMIMortality, minor or minimal bleeding event5 daysAlexopoulos 2013 \[[@CR16]\]T2DM patients with ACSMajor bleeding, MACEs, BARC 1 bleeding15 daysAlexopoulos 2012B \[[@CR17]\]T2DM patients with non-STEMIMajor bleeding, MACEs, BARC 1 and 2 bleeding15 daysBonello 2015 \[[@CR18]\]T2DM patients with ACSCardiovascular death, MACEs, BARC \> 2 bleeding events, stroke30 daysConrotto 2018 \[[@CR19]\]T2DM patients with ACSMortality, MI, MACEs, stroke, BARC 2--5 bleeding19 monthsDimitroulis 2018 \[[@CR20]\]T2DM patients with STEMIMACCEs, all-cause mortality, cardiovascular death, MI, stroke, TIMI major and TIMI minor bleeding12 monthsFranchi 2016 \[[@CR21]\]T2DM patients with CADBARC 1--5 bleeding, dyspnea7 daysHochholzer 2017 \[[@CR22]\]T2DM patients with CADDeath, MI, TIMI major and minor bleeding, BARC 3--530 daysLaine 2014 \[[@CR23]\]T2DM patients with ACSDeath, MACEsIn-hospitalMotovska 2016 \[[@CR24]\]T2DM patients with AMITIMI major, TIMI minor, TIMI minimal bleeding, BARC 1--5, MACEs, MI, stroke, death30 daysParodi 2013 \[[@CR25]\]T2DM patients with STEMIDeath, MI, stroke, TIMI major, minor, minimal bleeding, dyspneaIn-hospitalPerl 2014 \[[@CR26]\]T2DM patients with AMIBleeding events30 daysSong 2017 \[[@CR27]\]T2DM patients with ACSMortality365 days*PCI* percutaneous coronary intervention, *T2DM* type 2 diabetes mellitus, *STEMI* ST segment elevated myocardial infarction, *ACS* acute coronary syndrome, *CAD* coronary artery disease, *AMI* acute myocardial infarction, *MACEs* major adverse cardiac events, *MACCEs* major adverse cardiovascular and cerebrovascular events, *BARC* bleeding defined according to the Bleeding Academic Research Consortium, *TIMI* Thrombolysis in Myocardial Infarction, *MI* myocardial infarction

The following endpoints were assessed in this analysis:MortalityMyocardial infarction (MI)Major adverse cardiac events (MACEs) consisting of mortality, MI, and revascularizationStrokeTotal bleeding events including all bleeding events which were reportedThrombolysis in Myocardial Infarction (TIMI) \[[@CR11]\] defined minor bleedingTIMI defined major bleeding \[[@CR11]\]Minor bleeding defined according to the Bleeding Academic Research Consortium (BARC 1 and 2) \[[@CR12]\]Major bleeding defined according to the Bleeding Academic Research Consortium (BARC \> 2) \[[@CR12]\]Minimal bleeding (any type of minimal bleeding)

Data Extraction and Quality Assessment {#Sec5}
--------------------------------------

Relevant data including the number of participants with T2DM, the total number of T2DM participants assigned to the ticagrelor group, the total number of T2DM participants assigned to the prasugrel group, the baseline features of the participants, the total number of events associated with mortality, MI, MACEs, stroke, and bleeding outcomes were carefully extracted by four reviewers.

Data were cross-checked by all the reviewers. Any disagreements which followed were resolved by discussion.

The methodological quality of the trials was assessed with reference to the recommendations of the Cochrane Collaboration \[[@CR13]\].

Statistical Analysis {#Sec6}
--------------------

Statistical analysis was carried out by the Revman software (version 5.3). Odds ratios (OR) and 95% confidence intervals (CI) were used to represent the data during subgroup analysis.

Heterogeneity was assessed by the*Q* statistic test. A result reporting a*P* value less or equal to 0.05 was considered statistically significant whereas any *P* value greater than 0.05 was considered statistically insignificant.

Heterogeneity was also assessed by the *I*^2^ statistic test. Heterogeneity was considered to be high if the *I*^2^ value was high. A low heterogeneity was represented by a lower *I*^2^ value.

A fixed statistical model was used if *I*^2^ was less than 50% whereas a random statistical model was used if *I*^2^ was greater than 50%.

Sensitivity analysis was carried out by an exclusion method. Each study was excluded one by one and a new analysis was carried out each time to observe for any significant change in the main results.

Publication bias was visually assessed by observing funnel plots.

Compliance with Ethical Guidelines {#Sec7}
----------------------------------

Ethical approval was not required for this study since it did not involve experiments with animals or humans performed by any of the authors.

Results {#Sec8}
=======

Search Outcomes {#Sec9}
---------------

Searched outcomes (Preferred Reporting Items for Systematic reviews and Meta-Analyses: PRISMA guideline) \[[@CR14]\] resulted in a total of 745 articles. Following a careful assessment of the titles and abstracts, 698 articles were eliminated. Forty-seven (47) full-text articles were assessed for eligibility. Further eliminations were carried out for the following reasons: meta-analyses (3), letters of correspondence (3), reported only platelet outcomes (11), reported data which could not be used in this analysis (2), duplicated studies (15). Finally, 13 articles \[[@CR15]--[@CR27]\] were selected for this analysis as shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow diagram representing the flow of study selection

Main and Baseline Features of the Studies and Participants {#Sec10}
----------------------------------------------------------

A total of 2004 participants with T2DM were included in this analysis; of these, 996 T2DM participants were assigned to ticagrelor whereas 1008 T2DM participants were assigned to prasugrel. The enrollment period was between years 2012 and 2016 as shown in Table [2](#Tab2){ref-type="table"}. Table [2](#Tab2){ref-type="table"} lists the number of T2DM participants extracted from each study.Table 2General features of the studiesStudiesType of studyParticipants' enrollment periodNo. of T2DM participants assigned to ticagrelor group (*n*)No. of T2DM participants assigned to prasugrel group (*n*)Alexopoulos 2012NRT--32Alexopoulos 2013NRT20121515Alexopoulos 2012BRT201264Bonello 2015RT20143144Conrotto 2018NRT2012--2016386386Dimitroulis 2018NRT2012--20153032Franchi 2016RT2013--20152426Hochholzer 2017RT2016109Laine 2014RT2012--20135050Motovska 2016RT2013--2016124127Parodi 2013RT201236Perl 2014NRT--1917Song 2017NRT2013--2014295290Total no. of participants (*n*)9961008*NRT* non-randomized trial, *RT* randomized trial, *T2DM* type 2 diabetes mellitus

Table [3](#Tab3){ref-type="table"} lists the baseline features of the T2DM participants. The mean age of the patients varied from 55.8 to 71.8 years. The majority of participants were male. The percentages of participants with hypertension, dyslipidemia, and a smoking history are reported in Table [3](#Tab3){ref-type="table"}.Table 3Baseline features of the participantsStudiesAge (years)Male (%)HBP (%)DSL (%)CS (%)Tica/PrasuTica/PrasuTica/PrasuTica/PrasuTica/PrasuAlexopoulos 201258.0/61.086.0/74.043.0/44.046.0/59.064.0/48.0Alexopoulos 201360.9/65.493.3/93.373.3/66.746.7/53.333.3/40.0Alexopoulos 2012B55.8/57.492.9/82.157.1/53.667.9/42.964.3/42.9Bonello 201561.5/60.069.8/79.852.8/57.953.3/45.348.0/36.8Conrotto 201862.6/62.979.5/80.867.6/68.463.0/65.343.8/40.2Dimitroulis 201863.0/57.076.0/81.065.0/53.024.0/22.049.0/58.0Franchi 201659.0/59.072.0/72.093.0/93.087.0/87.024.0/24.0Hochholzer 201769.0/70.078.0/82.080.0/84.096.0/84.0--Laine 201464.8/62.866.0/86.080.0/70.056.0/62.028.0/28.0Motovska 201661.8/61.873.7/77.151.2/51.435.4/33.465.8/64.0Parodi 201367.0/67.076.0/80.072.0/60.040.0/20.036.0/36.0Perl 201463.2/57.580.8/79.063.5/43.563.5/59.734.6/51.6Song 201771.8/71.764.6/65.386.6/87.082.1/81.716.5/16.5*HBP* hypertension, *DSL* dyslipidemia, *CS* current smoker, *Tica* ticagrelor group, *Prasu* prasugrel group

Post-Interventional Clinical Outcomes and Bleeding Events Observed with Ticagrelor Versus Prasugrel in Patients with Type 2 Diabetes Mellitus {#Sec11}
---------------------------------------------------------------------------------------------------------------------------------------------

Following PCI, when the adverse clinical outcomes were assessed in T2DM patients who were assigned to ticagrelor versus prasugrel, mortality (OR 1.00, 95% CI 0.57--1.76; *P* = 0.99, *I*^2^ = 19%), MI (OR 0.86, 95% CI 0.42--1.75; *P* = 0.67, *I*^2^ = 0%), MACEs (OR 0.73, 95% CI 0.42--1.27; *P* = 0.27, *I*^2^ = 0%), and stroke (OR 0.72, 95% CI 0.20--2.59; *P* = 0.61, *I*^2^ = 0%) were not significantly different between the two different groups of antiplatelet agents as shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Post-interventional clinical outcomes observed with ticagrelor versus prasugrel in patients with type 2 diabetes mellitus

The post-interventional bleeding events were also assessed following ticagrelor or prasugrel use in these patients with T2DM. Total bleeding events (OR 0.87, 95% CI 0.55--1.40; *P* = 0.58, *I*^2^ = 6%), TIMI defined minor bleeding (OR 2.39, 95% CI 0.58--9.91; *P* = 0.23, *I*^2^ = 0%), TIMI defined major bleeding (OR 1.42, 95% CI 0.27--7.45; *P* = 0.68, *I*^2^ = 0%), BARC major bleeding (OR 0.55, 95% CI 0.22--1.36; *P* = 0.20, *I*^2^ = 0%), BARC minor bleeding (OR 1.44, 95% CI 0.52--3.99; *P* = 0.48, *I*^2^ = 0%), and total minimal bleeding (OR 3.12, 95% CI 0.55--17.59; *P* = 0.20, *I*^2^ = 0%) were not significantly different as shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Post-interventional bleeding events observed with ticagrelor versus prasugrel in patients with type 2 diabetes mellitus

The results are summarized in Table [4](#Tab4){ref-type="table"}.Table 4Summarized results of the analysis comparing the outcomes observed with ticagrelor versus prasugrel in patients with type 2 diabetes mellitusEndpoints assessedTotal no. of studies (n)OR with 95% CI*P* value*I*^2^ value (%)Mortality91.00 (0.57--1.76)0.9919Myocardial infarction50.86 (0.42--1.75)0.670MACEs70.73 (0.42--1.27)0.270Stroke50.72 (0.20--2.59)0.610Total bleeding events120.87 (0.55--1.40)0.586TIMI minor bleeding42.39 (0.58--9.91)0.230TIMI major bleeding41.42 (0.27--7.45)0.680BARC bleeding (minor)41.44 (0.52--3.99)0.480BARC bleeding (major)50.55 (0.22--1.36)0.200Minimal bleeding33.12 (0.55--17.59)0.200*OR* odds ratios, *CI* confidence intervals, *TIMI* Thrombolysis in Myocardial Infarction, *BARC* bleeding defined by the Bleeding Academic Research Consortium, *MACEs* major adverse cardiac events

Sensitivity Analysis and Publication Bias {#Sec12}
-----------------------------------------

When each study was excluded one by one and a new analysis was carried out, consistent results were obtained throughout. Publication bias was visually assessed through funnel plots. Based on this assessment, a low evidence of publication bias was observed across all the studies that assessed the post-interventional clinical outcomes and bleeding events observed with ticagrelor versus prasugrel in these patients with T2DM as shown in Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}.Fig. 4Funnel plot representing publication bias Fig. 5Funnel plot representing publication bias

Discussion {#Sec13}
==========

The post-interventional clinical outcomes and bleeding events observed with ticagrelor versus prasugrel were compared in patients with T2DM. Findings of this analysis showed no significant difference in mortality, MI, MACEs, stroke, total bleeding events, TIMI defined major and minor bleedings, BARC major and minor bleedings as well as no significant difference in minimal bleeding events.

Recently, the Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention (PRAGUE-18) Trial which compared these two newer potent antiplatelets with clopidogrel showed that the latter was inferior in terms of efficacy \[[@CR28]\]. However, bleeding risk was increased with ticagrelor and prasugrel in comparison with clopidogrel. In the PRAGUE-18 trial, ticagrelor and prasugrel were compared with clopidogrel. But in this analysis, ticagrelor was compared with prasugrel and the results showed no significant difference in patients with T2DM.

A subgroup analysis of a randomized, open-label, crossover study conducted in different US centers and which included 21 patients with T2DM showed that even with stable coronary artery disease, ticagrelor could achieve a faster onset and a greater magnitude of platelet inhibition in comparison to clopidogrel \[[@CR29]\], which would be an advantage for patients with T2DM who were more prone to platelet hyperactivity \[[@CR9]\]. It should be noted that hyperactive platelets in patients with T2DM were due to the increased expression of the platelet surface adhesion receptors and molecules, and due to enhanced production of thromboxane as well as thrombin, resulting in easy and rigorous aggregation of platelets. Increased prostaglandin synthetase activity, increased arachiodonic acid metabolism, and decreased antioxidant levels have also been linked to the mechanisms involved in hyperactive platelets in patients with T2DM \[[@CR30]\]. Other explanations for platelet dysfunctions were related to the production of immature, larger platelets by the bone marrow, and activation of platelets due to repeated vascular damage in these patients with T2DM \[[@CR31]\].

However, the controversy associated with these new potential antiplatelet agents does not appear to be reaching an end soon. Data from the large, multicenter, international Registry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) having a longer follow-up of the participants (19 months) showed major adverse cardiac events to be similar between ticagrelor and prasugrel in patients with T2DM \[[@CR19]\]. However, ticagrelor was associated with a lower risk of both death and BARC bleeding \[[@CR19]\]. Moreover, a review of literature based on clinical trials showed that ticagrelor and prasugrel significantly reduced ischemic events in comparison to clopidogrel, and ticagrelor and clopidogrel showed comparable bleeding risks \[[@CR32]\]. However, prasugrel was associated with a significantly higher major bleeding risk. This effect was mainly observed in female and older patients \[[@CR33]\]. Nevertheless, this current analysis, while directly comparing ticagrelor versus prasugrel in patients with T2DM, did not show any significant difference in bleeding events.

Limitations {#Sec14}
-----------

This analysis has certain limitations. First of all, because of the small total number of participants, the results might have been affected. Secondly, the dosage of ticagrelor and prasugrel might have had an influence on the outcomes. Additionally, the use of other antiplatelet and other cardiac medications was ignored in this analysis. Also, a few studies reported a crossover from prasugrel to ticagrelor and vice versa. The follow-up time period was also not equivalent in the studies. Another limitation could be the fact that this analysis included data which were extracted from both randomized and non-randomized trials.

Conclusions {#Sec15}
===========

Ticagrelor and prasugrel were not associated with significantly different adverse clinical outcomes and bleeding events in these patients with T2DM. Therefore, both antiplatelet agents might safely be used in patients with T2DM following coronary intervention. However, this head-to-head comparison still remains a major challenge which should be resolved in larger clinical trials.
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